Brief: Evofem Biosciences Expects Record High Phexxi Prescriptions And Strong Net Revenue Growth In Fourth Quarter 2021
09/12/2021 13:15
Dec 9 (Reuters) - Evofem Biosciences Inc EVFM.O :
* EVOFEM BIOSCIENCES EXPECTS RECORD HIGH PHEXXI
PRESCRIPTIONS AND
STRONG NET REVENUE GROWTH IN FOURTH QUARTER 2021
* EVOFEM BIOSCIENCES INC - EXPECT TO MEET OR EXCEED CURRENT
ANALYST CONSENSUS ESTIMATE OF NET REVENUE IN Q4
* EVOFEM BIOSCIENCES INC - REDUCING QUARTERLY NET CASH BURN
RATE
AND EXPECT IT WILL DECREASE BY AT LEAST $10 MILLION FROM Q3
LEVELS STARTING IN Q4
Source text for Eikon: ID:nPnbzNFZCa
Further company coverage: EVFM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evofem Biosciences
See all newsBrief: Evofem Biosciences Adds Additional Manufacturing Capacity For Phexx To Support Global Growth Strategy
Brief: HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition Of Evofem Notes
Evofem Biosciences Q1 sales edge up on higher pricing
Evofem Biosciences Q3 net sales rise
Brief: Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting